At a glance
ClinicalIndex Comparison Record- ✓Age 6-18 years
- ✓Diagnosis of asthma with at least two prior ED or primary care visits for asthma
- ✓ED attending physician decision to initiate continuous albuterol after standard ED treatment
- ✕Plan for continuous IV beta-agonist infusion (e.g., terbutaline)
- ✕Plan for PICU admission
- ✕Allergy or contraindication to racemic albuterol or levalbuterol
- ✕Concurrent disease: sickle cell, cystic fibrosis, or cardiac disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Continuous Levalbuterol for Treatment of Status Asthmaticus in Children
In Brief
A Phase 4 clinical trial evaluating Racemic albuterol (R+S albuterol) and Levalbuterol (R albuterol) for Asthma. Completed, enrolled 81 participants across 1 site.
Detailed Summary
This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis * Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses * Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. * Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol.
Study Details
Timeline
Interventions
20mg/hr continuous racemic albuterol
10mg/hr continuous nebulized levalbuterol